Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

1

Tildrakizumab significantly improves both skin clearance and various patient-reported outcomes in individuals with moderate-to-severe chronic plaque psoriasis.
2

The study found a strong correlation between PASI scores and patient-reported outcome measures, particularly in the early treatment phase.
3

Improvements in quality of life, symptoms, and sleep were observed alongside clinical efficacy, highlighting the importance of patient-centered care.
4

Reliance solely on PASI may underestimate the full impact of biologic therapy, emphasizing the need for integrating PROMs in psoriasis management.
5

The prospective study involved 33 biologic-naïve patients, assessing clinical and patient-reported outcomes over a year of tildrakizumab treatment.

Dermatology And Therapy (Springer)

by Paola Facheris, Francesco Piscazzi, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Riccardo G. Borroni
April 24, 2026

1